Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in:

01-04-2014 | Original Paper

Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis

Auteurs: Tomoya Hirota, Jeremy Veenstra-VanderWeele, Eric Hollander, Taro Kishi

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 4/2014

Abstract

Electroencephalogram-recorded epileptiform activity is common in children with autism spectrum disorder (ASD), even without clinical seizures. A systematic literature search identified 7 randomized, placebo-controlled trials of antiepileptic drugs (AEDs) in ASD (total n = 171), including three of valproate, and one each of lamotrigine, levetiracetam, and topiramate. Meta-analysis revealed no significant difference between medication and placebo in four studies targeting irritability/agitation and three studies investigating global improvement, although limitations include lack of power and different medications with diverse actions. Across all seven studies, there was no significant difference in discontinuation rate between two groups. AEDs do not appear to have a large effect size to treat behavioral symptoms in ASD, but further research is needed, particularly in the subgroup of patients with epileptiform abnormalities.

vorige artikel Therapeutic Horseback Riding Outcomes of Parent-Identified Goals for Children with Autism Spectrum Disorder: An ABA′ Multiple Case Design Examining Dosing and Generalization to the Home and Community

volgende artikel STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

Aman, M. G., Lam, K. S., & Van Bourgondien, M. E. (2005). Medication patterns in patients with autism: temporal, regional, and demographic influences. Journal of child and adolescent psychopharmacology, 15, 116–126. doi: 10.1089/cap.2005.15.116. PubMedCrossRef

Anagnostou, E., Esposito, K., Soorya, L., Chaplin, W., Wasserman, S., & Hollander, E. (2006). Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. Journal of Clinical Psychopharmacology, 26, 444–446. doi: 10.1097/01.jcp.0000227703.72117.bc. PubMedCrossRef

Association, A.P. (1994). DSM-IV-TR.

Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 31, 175–181. PubMedCrossRef

Bolton, P. F., & Griffiths, P. D. (1997). Association of tuberous sclerosis of temporal lobes with autism and atypical autism. Lancet, 349, 392–395. doi: 10.1016/S0140-6736(97)80012-8. PubMedCrossRef

Chez, M. G., Chang, M., Krasne, V., Coughlan, C., Kominsky, M., & Schwartz, A. (2006). Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. Epilepsy & behavior : E&B, 8, 267–271. doi: 10.1016/j.yebeh.2005.11.001. CrossRef

Ching, H., T. Pringsheim (2012). Aripiprazole for autism spectrum disorders (ASD). Cochrane database of systematic reviews 5, CD009043 doi: 10.1002/14651858.CD009043.pub2.

DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177–188. PubMedCrossRef

Frankenburg, F. R., & Zanarini, M. C. (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. The Journal of clinical psychiatry, 63, 442–446. PubMedCrossRef

Hartley-McAndrew, M., & Weinstock, A. (2010). Autism spectrum disorder: Correlation between aberrant behaviors, EEG abnormalities and seizures. Neurology international, 2, e10. doi: 10.4081/ni.2010.e10. PubMedCentralPubMedCrossRef

Hellings, J. A., et al. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of child and adolescent psychopharmacology, 15, 682–692. doi: 10.1089/cap.2005.15.682. PubMedCrossRef

Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557–560. doi: 10.1136/bmj.327.7414.557. PubMedCentralPubMedCrossRef

Hollander, E., Dolgoff-Kaspar, R., Cartwright, C., Rawitt, R., & Novotny, S. (2001a). An open trial of divalproex sodium in autism spectrum disorders. The Journal of clinical psychiatry, 62, 530–534. PubMedCrossRef

Hollander, E., Soorya, L., Wasserman, S., Esposito, K., Chaplin, W., & Anagnostou, E. (2006). Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum, 9, 209–213. doi: 10.1017/S1461145705005791. CrossRef

Hollander, E., Swann, A. C., Coccaro, E. F., Jiang, P., & Smith, T. B. (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. The American journal of psychiatry, 162, 621–624. doi: 10.1176/appi.ajp.162.3.621. PubMedCrossRef

Hollander, E., et al. (2001b). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. The Journal of clinical psychiatry, 62, 199–203. PubMedCrossRef

Hollander, E., et al. (2003). Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 28, 1186–1197. doi: 10.1038/sj.npp.1300153. CrossRef

Hollander, E., et al. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35, 990–998. doi: 10.1038/npp.2009.202. CrossRef

Huband, N., M. Ferriter, R. Nathan, H. Jones (2010). Antiepileptics for aggression and associated impulsivity. Cochrane database of systematic reviews, CD003499 doi: 10.1002/14651858.CD003499.pub3.

Jesner, O.S., M. Aref-Adib, E. Coren (2007). Risperidone for autism spectrum disorder. Cochrane database of systematic reviews, CD005040 doi: 10.1002/14651858.CD005040.pub2.

Kagan-Kushnir, T., Roberts, S. W., & Snead, O. C, 3rd. (2005). Screening electroencephalograms in autism spectrum disorders: evidence-based guideline. Journal of Child Neurology, 20, 197–206. PubMed

Kanemura, H., Sano, F., Tando, T., Sugita, K., & Aihara, M. (2013). Can EEG characteristics predict development of epilepsy in autistic children? European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 17, 232–237. doi: 10.1016/j.ejpn.2012.10.002. CrossRef

Lecavalier, L. (2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36, 1101–1114. doi: 10.1007/s10803-006-0147-5. PubMedCrossRef

Lieberman, J. A., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 353, 1209–1223. doi: 10.1056/NEJMoa051688. PubMedCrossRef

Maayan, L., & Correll, C. U. (2011). Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of child and adolescent psychopharmacology, 21, 517–535. doi: 10.1089/cap. 2011.0015. PubMedCrossRef

Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121, e441–e448. doi: 10.1542/peds.2007-0984. PubMedCentralPubMedCrossRef

Mazzone, L., & Ruta, L. (2006). Topiramate in children with autistic spectrum disorders. Brain & development, 28, 668. doi: 10.1016/j.braindev.2006.05.004. CrossRef

Myers, S. M., Johnson, C. P., & D. American Academy of Pediatrics Council on Children With. (2007). Management of children with autism spectrum disorders. Pediatrics, 120, 1162–1182. doi: 10.1542/peds.2007-2362. PubMedCrossRef

Rezaei, V., et al. (2010). Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34, 1269–1272. doi: 10.1016/j.pnpbp.2010.07.005. PubMedCrossRef

Robb, A. S. (2010). Managing irritability and aggression in autism spectrum disorders in children and adolescents. Developmental disabilities research reviews, 16, 258–264. doi: 10.1002/ddrr.118. PubMedCrossRef

Rosenberg, R. E., Mandell, D. S., Farmer, J. E., Law, J. K., Marvin, A. R., & Law, P. A. (2010). Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007–2008. Journal of Autism and Developmental Disorders, 40, 342–351. doi: 10.1007/s10803-009-0878-1. PubMedCrossRef

Rugino, T. A., & Samsock, T. C. (2002). Levetiracetam in autistic children: an open-label study. Journal of developmental and behavioral pediatrics : JDBP, 23, 225–230. PubMedCrossRef

Sharma, A., & Shaw, S. R. (2012). Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis. Journal of pediatric health care: official publication of National Association of Pediatric Nurse Associates & Practitioners, 26, 291–299. doi: 10.1016/j.pedhc.2011.02.008. CrossRef

Spence, S. J., & Schneider, M. T. (2009). The role of epilepsy and epileptiform EEGs in autism spectrum disorders. Pediatric Research, 65, 599–606. doi: 10.1203/PDR.0b013e31819e7168. PubMedCentralPubMedCrossRef

Sung, M., Fung, D. S., Cai, Y., & Ooi, Y. P. (2010). Pharmacological management in children and adolescents with pervasive developmental disorder. The Australian and New Zealand journal of psychiatry, 44, 410–428. doi: 10.3109/00048670903493330. PubMedCrossRef

Wasserman, S., et al. (2006). Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology, 21, 363–367. doi: 10.1097/01.yic.0000224787.13782.0f. PubMedCrossRef

Titel: Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
Auteurs: Tomoya Hirota
Jeremy Veenstra-VanderWeele
Eric Hollander
Taro Kishi
Publicatiedatum: 01-04-2014
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 4/2014
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-013-1952-2

Bohn Stafleu van Loghum

Tip

Swipe om te navigeren naar een ander artikel

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 4/2014

Social Smiling and Its Components in High-Risk Infant Siblings Without Later ASD Symptomatology

Brief Report: Atypical Expression of Distress During the Separation Phase of the Strange Situation Procedure in Infant Siblings at High Risk for ASD

Disturbed Interplay Between Mid- and High-Level Vision in ASD? Evidence from a Contour Identification Task with Everyday Objects

Brief Report: An Evaluation of TAGteach Components to Decrease Toe-Walking in a 4-Year-Old Child with Autism

Social Information Processing in Preschool Children Diagnosed with Autism Spectrum Disorder

Therapeutic Horseback Riding Outcomes of Parent-Identified Goals for Children with Autism Spectrum Disorder: An ABA′ Multiple Case Design Examining Dosing and Generalization to the Home and Community